[CAS NO. 2212020-52-3] Orforglipron
PRODUCTS SPECIFICATIONS [2212020-52-3]
DESCRIPTION [2212020-52-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 882.96 |
| Molecular Formula | C48H48F2N10O5 |
| SMILES | C[C@@H]1[C@](N2C3=CC=C([C@]4([H])CC(C)(OCC4)C)C=C3C=C2C(N5[C@H](C6=C(N7C(N(C8=CC=C(N(N=C9)C)C9=C8F)C=C7)=O)N(C%10=CC(C)=C(C(C)=C%10)F)N=C6CC5)C)=O)(C(N%11)=NOC%11=O)C1 |
Summary
Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is a GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67 [1] .
IC50 & Target
GLP-1 receptor [1]
In Vitro
Orforglipron is an incretin secreted from L cells of the small intestine when nutrients pass through the digestive tract, and glucose is transmitted via the GLP-1 receptor. Orforglipron exhibits various actions such as dependent gastric emptying delay, and feeding suppression [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03929744 | Eli Lilly and Company |
Healthy
|
June 12, 2019 | Phase 1 |
| NCT05051566 | Eli Lilly and Company|Quotient Sciences |
Healthy
|
September 16, 2021 | Phase 1 |
| NCT05313802 | Eli Lilly and Company |
Healthy|Obese
|
May 26, 2022 | Phase 1 |
| NCT04680767 | Eli Lilly and Company |
Healthy
|
March 29, 2021 | Phase 1 |
| NCT05573230 | Eli Lilly and Company |
Healthy
|
October 17, 2022 | Phase 1 |
| NCT05110794 | Eli Lilly and Company |
Healthy
|
November 5, 2021 | Phase 1 |
| NCT05048719 | Eli Lilly and Company |
Type 2 Diabetes
|
September 15, 2021 | Phase 2 |
| NCT05051579 | Eli Lilly and Company |
Obesity|Overweight and Obesity
|
September 29, 2021 | Phase 2 |
| NCT04426474 | Eli Lilly and Company |
Diabetes Mellitus, Type 2
|
October 8, 2020 | Phase 1 |
| NCT05341089 | Eli Lilly and Company |
Healthy
|
May 17, 2022 | Phase 1 |
| NCT05469126 | Eli Lilly and Company |
Healthy
|
August 1, 2022 | Phase 1 |
| NCT05086445 | Eli Lilly and Company |
Diabetes Mellitus, Type 2
|
November 12, 2021 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 113.26 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.1326 mL | 5.6628 mL | 11.3255 mL |
| 5 mM | 0.2265 mL | 1.1326 mL | 2.2651 mL |
| 10 mM | 0.1133 mL | 0.5663 mL | 1.1326 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2 mg/mL (2.27 mM); Clear solution
References